<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="6" ids="22696">Beh</z:chebi>Ã§et's disease is a systemic disorder with the histopathological correlate of leukocytoclastic <z:hpo ids='HP_0002633'>vasculitis</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Pathogenetically, besides a strong genetic component participation of the innate immune system and an autoinflammatory component are discussed </plain></SENT>
<SENT sid="2" pm="."><plain>The disease is most common in countries along the former silk route but in Germany the disease is rare (prevalence approximately 0.6/100,000) </plain></SENT>
<SENT sid="3" pm="."><plain>Oral aphthous <z:mpath ids='MPATH_579'>ulcers</z:mpath> are the main symptom, followed by skin manifestations, <z:hpo ids='HP_0003249'>genital ulcers</z:hpo> and <z:e sem="disease" ids="C0409702" disease_type="Disease or Syndrome" abbrv="">oligoarthritis</z:e> of large joints </plain></SENT>
<SENT sid="4" pm="."><plain>Severe manifestations, threatening quality of life and even life itself, are the gastrointestinal manifestations which often perforate, arterial, mainly pulmonary arterial <z:hpo ids='HP_0002617'>aneurysms</z:hpo> which cause life-threatening <z:mp ids='MP_0001914'>bleeding</z:mp>, <z:chebi fb="7" ids="29425,29426,29441,29447">CNS</z:chebi> manifestations and ocular disease, which with occlusive <z:chebi fb="46" ids="15035">retinal</z:chebi> <z:hpo ids='HP_0002633'>vasculitis</z:hpo> often leads to <z:hpo ids='HP_0000618'>blindness</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>For milder manifestations low-dose steroids and <z:chebi fb="0" ids="23359">colchicine</z:chebi> are used, for moderate manifestations such as <z:hpo ids='HP_0001369'>arthritis</z:hpo> or ocular disease not immediately threatening visual acuity, azathioprin or <z:chebi fb="0" ids="4031">cyclosporin A</z:chebi> are combined with steroids </plain></SENT>
<SENT sid="6" pm="."><plain>For severe manifestations, interferon-alpha, TNF-<z:chebi fb="68" ids="48706">antagonists</z:chebi> or cytotoxic drugs are recommended </plain></SENT>
<SENT sid="7" pm="."><plain>Interleukin 1 (IL-1) <z:chebi fb="68" ids="48706">antagonists</z:chebi> are currently being examined in clinical studies </plain></SENT>
</text></document>